Article
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Oncogene - 24 Feb 2011
von Bubnoff N, Gorantla S P, Engh R A, Oliveira T M, Thöne S, Aberg E, Peschel C, Duyster J
Abstract excerpt
Myeloproliferation with prominent eosinophilia is associated with rearrangements of PDGFR-A or -B. The most common rearrangement is FIP1L1-PDGFRA (FP). The majority of patients with PDGFR-rearranged myeloproliferation respond to treatment with imatinib. In contrast to BCR-ABL-positive chronic myelogenous leukemia, only few cases of imatinib resistance and mutations of the FP kinase domain have been described so...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.